Publication:
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

dc.contributor.authorLefort, M
dc.contributor.authorSharmin, S
dc.contributor.authorAndersen, J B
dc.contributor.authorVukusic, S
dc.contributor.authorCasey, R
dc.contributor.authorDebouverie, M
dc.contributor.authorEdan, G
dc.contributor.authorCiron, J
dc.contributor.authorRuet, A
dc.contributor.authorDe Sèze, J
dc.contributor.authorMaillart, E
dc.contributor.authorZephir, H
dc.contributor.authorLabauge, P
dc.contributor.authorDefer, G
dc.contributor.authorLebrun-Frenay, C
dc.contributor.authorMoreau, T
dc.contributor.authorBerger, E
dc.contributor.authorClavelou, P
dc.contributor.authorPelletier, J
dc.contributor.authorStankoff, B
dc.contributor.authorGout, O
dc.contributor.authorThouvenot, E
dc.contributor.authorHeinzlef, O
dc.contributor.authorAl-Khedr, A
dc.contributor.authorBourre, B
dc.contributor.authorCasez, O
dc.contributor.authorCabre, P
dc.contributor.authorMontcuquet, A
dc.contributor.authorWahab, A
dc.contributor.authorCamdessanché, J P
dc.contributor.authorMaurousset, A
dc.contributor.authorBen Nasr, H
dc.contributor.authorHankiewicz, K
dc.contributor.authorPottier, C
dc.contributor.authorMaubeuge, N
dc.contributor.authorDimitri-Boulos, D
dc.contributor.authorNifle, C
dc.contributor.authorLaplaud, D A
dc.contributor.authorHorakova, D
dc.contributor.authorHavrdova, E K
dc.contributor.authorAlroughani, R
dc.contributor.authorIzquierdo, G
dc.contributor.authorEichau, S
dc.contributor.authorOzakbas, S
dc.contributor.authorPatti, F
dc.contributor.authorOnofrj, M
dc.contributor.authorLugaresi, A
dc.contributor.authorTerzi, M
dc.contributor.authorGrammond, P
dc.contributor.authorGrand'Maison, F
dc.contributor.authorYamout, B
dc.contributor.authorPrat, A
dc.contributor.authorGirard, M
dc.contributor.authorDuquette, P
dc.contributor.authorBoz, C
dc.contributor.authorTrojano, M
dc.contributor.authorMcCombe, P
dc.contributor.authorSlee, M
dc.contributor.authorLechner-Scott, J
dc.contributor.authorTurkoglu, R
dc.contributor.authorSola, P
dc.contributor.authorFerraro, D
dc.contributor.authorGranella, F
dc.contributor.authorShaygannejad, V
dc.contributor.authorPrevost, J
dc.contributor.authorMaimone, D
dc.contributor.authorSkibina, O
dc.contributor.authorBuzzard, K
dc.contributor.authorVan der Walt, A
dc.contributor.authorKarabudak, R
dc.contributor.authorVan Wijmeersch, B
dc.contributor.authorCsepany, T
dc.contributor.authorSpitaleri, D
dc.contributor.authorVucic, S
dc.contributor.authorKoch-Henriksen, N
dc.contributor.authorSellebjerg, F
dc.contributor.authorSoerensen, P S
dc.contributor.authorHilt Christensen, C C
dc.contributor.authorRasmussen, P V
dc.contributor.authorJensen, M B
dc.contributor.authorFrederiksen, J L
dc.contributor.authorBramow, S
dc.contributor.authorMathiesen, H K
dc.contributor.authorSchreiber, K I
dc.contributor.authorButzkueven, H
dc.contributor.authorMagyari, M
dc.contributor.authorKalincik, T
dc.contributor.authorLeray, E
dc.date.accessioned2023-05-03T13:33:08Z
dc.date.available2023-05-03T13:33:08Z
dc.date.issued2022-05-30
dc.description.abstractNatalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. Overall, 5,148 relapsing-remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is fulfilled.
dc.identifier.doi10.1186/s12874-022-01623-8
dc.identifier.essn1471-2288
dc.identifier.pmcPMC9150358
dc.identifier.pmid35637426
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150358/pdf
dc.identifier.unpaywallURLhttps://bmcmedresmethodol.biomedcentral.com/counter/pdf/10.1186/s12874-022-01623-8
dc.identifier.urihttp://hdl.handle.net/10668/20266
dc.issue.number1
dc.journal.titleBMC medical research methodology
dc.journal.titleabbreviationBMC Med Res Methodol
dc.language.isoen
dc.organizationHospital Universitario Virgen Macarena
dc.page.number155
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCausal contrasts
dc.subjectCensoring
dc.subjectEffectiveness
dc.subjectIndication bias
dc.subjectMultiple sclerosis
dc.subjectPositivity assumption
dc.subjectPropensity score
dc.subject.meshFingolimod Hydrochloride
dc.subject.meshHumans
dc.subject.meshMultiple Sclerosis
dc.subject.meshMultiple Sclerosis, Relapsing-Remitting
dc.subject.meshNatalizumab
dc.subject.meshTreatment Outcome
dc.titleImpact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number22
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9150358.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format